ダウンロード数: 212
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
1440-1681.13405.pdf | 1.32 MB | Adobe PDF | 見る/開く |
タイトル: | The sphingosine-1-phosphate receptor modulator, FTY720, prevents the incidence of diabetes in Spontaneously Diabetic Torii rats |
著者: | Kobayashi, Kazuma Sasase, Tomohiko Ishii, Yukihito Katsuda, Yoshiaki Miyajima, Katsuhiro Yamada, Takahisa Ohta, Takeshi |
著者名の別形: | 太田, 毅 |
キーワード: | diabetes immunomodulation SDT rat sphingosin-1-phosphate receptor modulator |
発行日: | Jun-2021 |
出版者: | Wiley |
誌名: | Clinical and Experimental Pharmacology and Physiology |
巻: | 48 |
号: | 6 |
開始ページ: | 869 |
終了ページ: | 876 |
抄録: | The sphingosine-1-phosphate (S1P) receptor modulator regulates lymphocyte trafficking, resulting in its depletion from circulation, which ultimately causes immunosuppression. In this study, we investigated the preventive effect of fingolimod (FTY720) in the non-obese type 2 diabetic model, Spontaneously Diabetic Torii (SDT) rats. The S1P receptor modulator, FTY720 (0.3 mg/kg p.o.), was administered for 12 weeks to SDT rats from 5 to 17 weeks of age. Based on our findings, FTY720 could suppress the incidence of diabetes in SDT rats. Further, glucose intolerance was improved in FTY720-treated SDT rats at 14 weeks of age. Based on the haematological and histological analyses performed at 17 to 18 weeks of age, a decrease in lymphocytes and monocytes in the peripheral blood and a decrease in lymphocyte and atrophy in spleen occurred in the FTY720-treated SDT rats. Furthermore, the pancreatic changes, such as inflammation, atrophy, and fibrosis in islets observed in SDT rats were improved by FTY720 treatment. These findings suggest that the immunomodulatory effects of FTY720 reduced the pancreatic lesion in SDT rats, thereby demonstrating its preventive effect against diabetes. The development of diabetes in SDT rats is related to disorders of the immune system. However, the S1P receptor modulator may be useful for treating type 2 diabetes. |
著作権等: | This is the peer reviewed version of the following article: [Clinical and Experimental Pharmacology and Physiology, 48(6), 869-876, June 2021], which has been published in final form at https://doi.org/10.1111/1440-1681.13405. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. The full-text file will be made open to the public on 12 October 2021 in accordance with publisher's 'Terms and Conditions for Self-Archiving'. This is not the published version. Please cite only the published version. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。 |
URI: | http://hdl.handle.net/2433/263146 |
DOI(出版社版): | 10.1111/1440-1681.13405 |
PubMed ID: | 32920892 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。